Blackrock Inc vs 10X Genomics Inc — how do they compare? Blackrock Inc trades at $1,151.21 (market cap $177.92B), while 10X Genomics Inc trades at $57.6 (market cap $7.61B). The key difference: Blackrock Inc is far larger — about 23.4× 10X Genomics Inc's market cap, and Blackrock Inc pays a 2% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| BLK | TXG | |
|---|---|---|
Market Cap | $177.92B | $7.61B |
Volume | 641,547 | — |
Sector | Financials | Health |
52-Week High | $1.20K | $58.57 |
52-Week Low | $922.90 | $11.34 |
Enterprise Value | $179.02B | $7.14B |
Dividend Yield | 2% | — |
Signals from Pluang's Aura AI — not financial advice
BLK trades at $1,131.40, down slightly by 0.44% today, with a bullish technical signal from moving averages and strong analyst support. The company reported revenue of $24.22 billion for 2025, with net income of $5.55 billion, and has consistently beaten EPS estimates in recent quarters. Recent news highlights BlackRock's involvement in a major AI financing initiative with Nvidia and other firms.
The outlook remains positive given strong earnings performance and a consensus buy rating from analysts, with a price target of $1,350. Key risks include potential legal challenges from investor lawsuits and volatile cash flow trends, but institutional confidence and strategic partnerships provide a solid foundation for growth.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Trailing returns across standard periods
Latest headlines on both assets
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →